In the BioHarmony Drug Report Database
Galcanezumab
Emgality (galcanezumab) is an antibody pharmaceutical. Galcanezumab was first approved as Emgality on 2018-09-27. It is used to treat cluster headache in the USA. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
Trade Name
|
Emgality |
|---|---|
Common Name
|
galcanezumab |
ChEMBL ID
|
CHEMBL3707328 |
Indication
|
cluster headache, migraine disorders |
Drug Class
|
Monoclonal antibodies: humanized, neural indications |
Image (chem structure or protein)
